Lates News

According to Jijng AI, OpenSecurities issued a research report on January 28, giving Kailai Ying (002821.SZ) a "buy" rating. The rating reasons mainly include: 1) Small molecule cornerstone solid, conventional business resilience highlighted, signed orders stabilized and rebounded; 2) Emerging business strong growth, peptide production capacity expansion to seize the GLP-1 opportunity, layout at the forefront of small nucleic acid field; 3) The industry investment and financing environment is gradually warming, globalization layout and technology platform construction fortify the moat. (Daily Economic News)